DOCSLIB.ORG

Randomized Controlled Pilot Trial of Cabergoline, Hydergine and Levodopa/Carbidopa: Los Angeles Cocaine Rapid Efficacy Screening

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Randomized Controlled Pilot Trial of Cabergoline, Hydergine and Levodopa/Carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Blackwell Science, LtdOxford, UKADDAddiction1359-6357© 2005 Society for the Study of Addiction 100•••• Original Article Cabergoline, hydergine, levodopa/carbidopa Steven Shoptaw et al. RESEARCH REPORT Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST) Steven Shoptaw1, Donnie W. Watson2, Chris Reiber1, Richard A. Rawson1, Margaret A. Montgomery3, Maria D. Majewska3 & Walter Ling1 UCLA Integrated Substance Abuse Programs, Los Angeles, CA1 , Friends Research Institute, Inc., Los Angeles, CA2 and National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA3 Correspondence to: ABSTRACT Steven Shoptaw PhD UCLA/Integrated Substance Abuse Programs Aim This study tested three dopaminergic medications against a common 11075 Santa Monica Blvd unmatched placebo condition: hydergine 1 mg three times daily (n = 15); Suite 200 levodopa/carbidopa 25/100 mg three times daily (n = 15); cabergoline 0.5 mg Los Angeles per week (n = 15); and placebo three times daily (n = 15) as potential pharma- CA 90025 USA cotherapies for cocaine dependence. E-mail: [email protected] Design The four-parallel group, Cocaine Rapid Efficacy Screening Trial (CREST) design featured a 2-week baseline period followed by randomization to an 8-week medication condition that included 1 hour per week of cognitive RESEARCH REPORT behavioral drug counseling. A safety evaluation was conducted 4 weeks after termination. Measures Outcomes included cocaine metabolites measured in urine, reten- tion and self-reports for drug use, cocaine craving, clinical improvement, mood and HIV risk behaviors. Results Participants assigned to receive cabergoline provided more urine sam- ples negative for cocaine metabolites (42.4%) than those assigned to receive pla- cebo (25.0%), a statistically significant difference after controlling for baseline differences in self-reported cocaine use (F = 2.95, df = 3; P = 0.05). Cabergoline- treated participants demonstrated a significant improvement over placebo from baseline to week 8 when measured using the Addiction Severity Index (ASI) employment subscale (overall change = - 0.09, SD = 0.10, t = 2.36, P < 0.05). Safety and adverse event measures showed similar rates and types of complaints by treatment condition. Conclusions These results, combined with the apparent safety of cabergoline when used with this population, provide empirical support for conducting a larger study of the medication. KEYWORDS Cabergoline, cocaine, hydergine, levodopa/ carbidopa, out-patient. INTRODUCTION the nucleus accumbens are part of a cascade that com- prises the brain’s reward circuitry (see Self & Nestler Cocaine produces multiple effects on the brain and the 1995). Substances including opiates, ethanol, nicotine relationship of these to the development of cocaine depen- (Calabresi et al. 1989; Nisell et al. 1994; Pontieri et al. dence is not entirely understood. It is known that dopam- 1996) and cannabinoids (Chen et al. 1990) also indirectly ine neurons in the ventral tegmental area that project into cause release of dopamine from the ventral tegmental area © 2005 Society for the Study of Addiction Addiction, 100 (Suppl. 1), 78–90 Cabergoline, hydergine, levodopa/carbidopa 79 (Imperato & DiChiara 1986; Leone et al. 1991; Johnson & itary adenomas (Colao et al. 2000), and in the control of North 1992). Cocaine acts to inhibit the uptake of dopam- clinical and hormonal features of dopamine-sensitive ine after its release into the synapse, thereby increasing acromegalic patients (Muratori et al. 1997). Among synaptic dopamine at the nucleus accumbens. humans, cabergoline improves motor functions damaged Medications that modify dopamine neurotransmitter by Parkinson’s disease when used alone or in combination levels should alter cocaine use in humans (see Jentsch with L-dopa in a dose-related fashion (Inzelberg et al. & Taylor 1999). Laboratory rats self-administer both 1995; Ahlskog et al. 1996; Hutton et al. 1996; Steiger et al. amphetamine (Hoebel et al. 1983) and dopamine (Dwor- 1996) and relieved Parkinsonian symptoms in mon- kin et al. 1986) directly into the nucleus accumbens. keys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- Bilateral injections of dopamine receptor antagonists into induced nigrostriatal depletion (Calon et al. 2000). These the nucleus accumbens or lesions of the ventral tegmen- reports indicate that cabergoline is efficient in ameliorating tal area neurons that project to the nucleus accumbens disorders associated with dopamine deficiency and hence attenuate the reinforcing effects of cocaine (Dworkin et al. is an appropriate candidate for this screening trial. 1988); yet these same dopaminergic medications, when evaluated in treatment-seeking, cocaine-dependent Levodopa/carbidopa humans, show no effects in altering cocaine use. As yet there is no consistent evidence that dopaminergic medi- Levodopa/carbidopa (Sinemet®) is an approved medica- cations reduce cocaine use when evaluated in placebo- tion for the treatment of symptoms of Parkinson’s disease. controlled, randomized trials (Ling & Shoptaw 1997, de Levodopa is a precursor of dopamine and increases the Lima et al. 2002). store of available central dopamine in dopamine-deficient The slate of approved medications with dopaminergic individuals (Cotzias et al. 1969). Carbidopa is a decarbox- activity has yet to be completely studied. Hence, to study ylase inhibitor that acts peripherally to prevent degrada- dopaminergic medications previously untested for tion of levodopa, thereby increasing efficiency of central cocaine dependence, the Los Angeles site for the Clinical dopamine availability. In theory, the dopamine precursor Rapid Efficacy Screening Trial (CREST) program funded action of levodopa/carbidopa may allow for a more rapid by the National Institute on Drug Abuse evaluated three return to natural dopamine levels following cocaine dis- agents compared to a common placebo condition for continuation. An early placebo-controlled, randomized their ability to reduce cocaine use: cabergoline 0.5 mg study of 30 cocaine-dependent participants appearing at once weekly (Dostinex®, a long-acting dopamine receptor an emergency room within 24 hours of their last use of agonist that acts postsynaptically), levodopa/carbidopa cocaine reported no statistically significant differences in 25 mg/100 mg three times daily (Sinemet®, a dopamine ratings of ‘crash’, ‘depression’, ‘anergia’ or ‘craving’ precursor that increases dopamine concentrations pre- when treated using 400 mg levodopa and 100 mg carbi- synaptically) and hydergine 1 mg three times daily (a dopa or placebo (Wolfsohn et al. 1993). Although there mixed dopamine agonist and antagonist). are no published reports of outcomes using levodopa/car- bidopa with cocaine-dependent individuals, its ability to alter dopamine availability make this medication another Evidence supporting these medications appropriate candidate for the screening trial. Cabergoline Hydergine Cabergoline (Dostinex®), a medication with a half-life of 63–69 hours, is approved for treating Parkinson’s disease Hydergine enhances cognition and improves memory and hyperprolactinemia. Cabergoline binds to D2 dopam- in patients with dementia (Thienhaus et al. 1987; ine receptors in the pituitary, which in turn may account Schneider & Olin 1994). In addition, hydergine is thought for its inhibition of prolactin secretion and its use as a to increase cerebral glucose metabolism in the cortex prolactin-lowering agent (Webster et al. 1994). Although (Nagasawa et al. 1990), to improve cognitive deficits and there are no published reports on the use of cabergoline as mood symptoms in elderly patients (Rouy et al. 1989), to a cocaine pharmacotherapy, bromocriptine, another D2 improve sleep and depression in ethanol-related enceph- dopamine receptor agonist, reduced ratings of cocaine alopathy (Datta et al. 1987) and to maintain physical and craving among cocaine-dependent individuals in a double- mental health among healthy individuals (Huber et al. blind, placebo-controlled study (Dackis et al. 1987). 1986). Hydergine enhances cerebral blood flow by caus- Cabergoline is superior to bromocriptine in efficacy and ing vasodilation and its properties as a mixed agonist/ tolerability, and may be regarded as the treatment of choice antagonist at postsynaptic D1 receptors and pre- and for hyperprolactinemic disorders, either idiopathic postsynaptic D2 receptors may account for its ability to (Webster et al. 1993, 1994; Webster 1999) or due to pitu- correct monoamine disturbances in the central nervous © 2005 Society for the Study of Addiction Addiction, 100 (Suppl. 1), 78–90 80 Steven Shoptaw et al. system (Goldstein 1985; Markstein 1985). There are no ications for cocaine dependence. Interested individuals published reports of prior use of hydergine with human telephoned a toll-free number and scheduled an intake cocaine-dependent individuals. The activity of hydergine appointment to meet with a counselor to discuss the at selective dopamine receptor sites also makes this treatment research and meet with a study physician to medication appropriate for screening. conduct the consent process. The design for the CREST paradigm features multiple active medication conditions and a common placebo to Clinical trial phase support efficient safety and efficacy evaluations. The CREST objective was to determine whether any of the The study employed a flexible 2-week,
Load more

Recommended publications
  • Potentially Harmful Drugs in the Elderly: Beers List
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− March 2019 ~ Resource #350301 Potentially Harmful Drugs in the Elderly: Beers List In 1991, Dr. Mark Beers and colleagues published a methods paper describing the development of a consensus list of medicines considered to be inappropriate for long-term care facility residents.12 The “Beers list” is now in its sixth permutation.1 It is intended for use by clinicians in outpatient as well as inpatient settings (but not hospice or palliative care) to improve the care of patients 65 years of age and older.1 It includes medications that should generally be avoided in all elderly, used with caution, or used with caution or avoided in certain elderly.1 There is also a list of potentially harmful drug-drug interactions in seniors, as well as a list of medications that may need to be avoided or have their dosage reduced based on renal function.1 This information is not comprehensive; medications and interactions were chosen for inclusion based on potential harm in relation to benefit in the elderly, and availability of alternatives with a more favorable risk/benefit ratio.1 The criteria no longer address drugs to avoid in patients with seizures or insomnia because these concerns are not unique to the elderly.1 Another notable deletion is H2 blockers as a concern in dementia; evidence of cognitive impairment is weak, and long-term PPIs pose risks.1 Glimepiride has been added as a drug to avoid. Some drugs have been added with cautions (dextromethorphan/quinidine, trimethoprim/sulfamethoxazole), and some have had cautions added (rivaroxaban, tramadol, SNRIs).
    [Show full text]
  • Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
    BIRTHDAY 83 CHIMIA 2006, 60, No. 1/2 Chimia 60 (2006) 83–87 © Schweizerische Chemische Gesellschaft ISSN 0009–4293 Albert Hofmann’s Pioneering Work on Ergot Alkaloids and Its Impact on the Search of Novel Drugs at Sandoz, a Predecessor Company of Novartis Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday Rudolf K.A. Giger* and Günter Engela Abstract: The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today. The complex chemical structures of ergot peptide alkaloids and their pluripotent pharmacological activity were a great challenge for Dr. Hofmann and his associates who sought to unravel the secrets of the ergot peptide alkaloids; a source of inspiration for the design of novel, selective and valuable medicines. Keywords: Aminocyclole · Bromocriptine Parlodel® · Dihydroergotamine Dihydergot® · Dihydro ergot peptide alkaloids · Ergobasin/ergometrin · Ergocornine · Ergocristine · α- and β-Ergocryptine · Ergolene · Ergoline · Ergoloid mesylate Hydergine® · Ergotamine Gynergen® · Ergotoxine · Lisuride · Lysergic acid diethylamide LSD · Methylergometrine Methergine® · Methysergide Deseril® · Paspalic acid · Pindolol Visken® · Psilocybin · Serotonin · Tegaserod Zelmac®/Zelnorm® · Tropisetron Navoban® Fig. 1. Albert Hofmann in 1943, 1979 and 2001 (Photos in 2001 taken by J. Zadrobilek and P. Schmetz) Dr. Albert Hofmann (Fig. 1), born on From the ‘Ergot Poison’ to *Correspondence: Dr. R.K.A. Giger January 11, 1906, started his extremely Ergotamine Novartis Pharma AG NIBR Global Discovery Chemistry successful career in 1929 at Sandoz Phar- Lead Synthesis & Chemogenetics ma in the chemical department directed The scientific research on ergot alka- WSJ-507.5.51 by Prof.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Conditions, Impairments Or Considerations That Would Disqualify a Proposed Insured from Approval
    Nationwide YourLife CareMatters® Prequalification guide Conditions, impairments or considerations that would disqualify a proposed insured from approval In rare instances, there may be a history indicated for disqualification in this guide that you feel may qualify for a CareMatters® policy. These histories should be prescreened before an application is submitted. Histories not found in this prequalification guide will be given individual consideration. If you feel a history may be borderline for life and long-term care, please complete a prescreen with a CareMatters underwriter prior to submission of an application. For prescreens, call 1-855-381-5729. Include the prescreen reference number in the "Special Instructions Section" of the application, or prescreen via email at CMScreen@nationwide. com. Include a copy of the prescreen email reply with the application. The proposed insured must be a U.S. citizen or permanent green card holder (issued for 10 years or more) and be able to provide a copy of green card and Social Security/tax identification number card. Within the last five years, proposed insured has had, has been diagnosed as having or has been treated for: • Alcohol abuse or dependency • Cardiomyopathy • HIV positive, AIDS, ARC, severe • Paralysis, hemiplegia, paraplegia or • Cerebral palsy combined immunodeficiency, quadriplegia (excluding Bell's palsy) • Alzheimer's, dementia, senility, mild common variable immune • Cirrhosis of the liver • Parkinson's disease cognitive impairment (MCI), organic deficiency brain syndrome,
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Ergot Alkaloids: a Review on Therapeutic Applications
    European Journal of Medicinal Plants 14(3): 1-17, 2016, Article no.EJMP.25975 ISSN: 2231-0894, NLM ID: 101583475 SCIENCEDOMAIN international www.sciencedomain.org Ergot Alkaloids: A Review on Therapeutic Applications Niti Sharma 1* , Vinay K. Sharma 1, Hemanth Kumar Manikyam 1 1,2 and Acharya Bal Krishna 1Patanjali Natural Coloroma Pvt. Ltd, Haridwar, Uttarakhand - 249404, India. 2University of Patanjali, Haridwar, Uttarakhand - 249402, India. Authors’ contributions This work was carried out in collaboration between all authors. Authors NS and VKS designed the study, wrote the first draft of the manuscript. Authors ABK and HKM supervised the study. All authors read and approved the final manuscript. Article Information DOI: 10.9734/EJMP/2016/25975 Editor(s): (1) Marcello Iriti, Professor of Plant Biology and Pathology, Department of Agricultural and Environmental Sciences, Milan State University, Italy. Reviewers: (1) Nyoman Kertia, Gadjah Mada University, Indonesia. (2) Robert Perna, Texas Institute of Rehabilitation Research, Houston, TX, USA. (3) Charu Gupta, AIHRS, Amity University, UP, India. Complete Peer review History: http://sciencedomain.org/review-history/14283 Received 28 th March 2016 Accepted 12 th April 2016 Review Article st Published 21 April 2016 ABSTRACT Ergot of Rye is a plant disease caused by the fungus Claviceps purpurea which infects the grains of cereals and grasses but it is being used for ages for its medicinal properties. All the naturally obtained ergot alkaloids contain tetracyclic ergoline ring system, which makes them structurally similar with other neurotransmitters such as noradrenaline, dopamine or serotonin. Due to this structure homology these alkaloids can be used for the treatment of neuro related conditions like migraine, Parkinson’s disease etc.
    [Show full text]
  • Cover Next Page > Cover Next Page >
    cover next page > Cover title: The Psychopharmacology of Herbal Medicine : Plant Drugs That Alter Mind, Brain, and Behavior author: Spinella, Marcello. publisher: MIT Press isbn10 | asin: 0262692651 print isbn13: 9780262692656 ebook isbn13: 9780585386645 language: English subject Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. publication date: 2001 lcc: RC483.S65 2001eb ddc: 615/.788 subject: Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. cover next page > < previous page page_i next page > Page i The Psychopharmacology of Herbal Medicine < previous page page_i next page > cover next page > Cover title: The Psychopharmacology of Herbal Medicine : Plant Drugs That Alter Mind, Brain, and Behavior author: Spinella, Marcello. publisher: MIT Press isbn10 | asin: 0262692651 print isbn13: 9780262692656 ebook isbn13: 9780585386645 language: English subject Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. publication date: 2001 lcc: RC483.S65 2001eb ddc: 615/.788 subject: Psychotropic drugs, Herbs--Therapeutic use, Psychopharmacology, Medicinal plants--Psychological aspects. cover next page > < previous page page_ii next page > Page ii This page intentionally left blank. < previous page page_ii next page > < previous page page_iii next page > Page iii The Psychopharmacology of Herbal Medicine Plant Drugs That Alter Mind, Brain, and Behavior Marcello Spinella < previous page page_iii next page > < previous page page_iv next page > Page iv © 2001 Massachusetts Institute of Technology All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher. This book was set in Adobe Sabon in QuarkXPress by Asco Typesetters, Hong Kong and was printed and bound in the United States of America.
    [Show full text]
  • August 2021 California Signaturevalue 4 Tier HMO Formulary
    Pharmacy | Formulary | California 2021 California SignatureValue 4-Tier HMO Formulary Please note: This Formulary is accurate as of August 1, 2021 and is subject to change after this date. All previous versions of this Formulary are no longer in effect. Your estimated coverage and copay/coinsurance may vary based on the benefit plan you choose and the effective date of the plan. This Formulary can also be accessed online at myuhc.com > Pharmacy Information > Prescription Drug Lists > California plans > SignatureValue HMO plans. Plan-specific coverage documents may be accessed online at uhc.com/statedruglists > Small Group Plans > California. If you are a UnitedHealthcare member, please register or log on to myuhc.com, or call the toll-free number on your health plan ID card to find pharmacy information specific to your benefit plan. This Formulary is applicable to the following health insurance products offered by UnitedHealthcare: • SignatureValue • SignatureValue Advantage • SignatureValue Alliance • SignatureValue Flex • SignatureValue Focus • SignatureValue Harmony • SignatureValue Performance Updated 6/17/2021 6/21 © 2021 United HealthCare Services, Inc. All Rights Reserved. WF3890815-N Contents At UnitedHealthcare, we want to help you better understand your medication options. ..................................................... 3 How do I use my Formulary? ............................................. 4 What are tiers? ........................................................ 5 When does the Formulary change? ........................................ 5 Utilization Management Programs ......................................... 6 Your Right to Request Access to a Non-formulary Drug ....................... 6 Requesting a Prior Authorization or Step Therapy Exception ................... 7 How do I locate and fill a prescription through a retail network pharmacy? . 7 How do I locate and fill a prescription through the mail order pharmacy? . 7 How do I locate and fill a prescription at a specialty pharmacy? ...............
    [Show full text]
  • Preferred Drug List
    Comprehensive PREFERRED DRUG LIST Buckeye Health Plan PAGE 1 Buckeye Health Plan Pharmacy Program Buckeye Health Plan, Inc. (Buckeye) is committed to providing appropriate, high quality, and cost effective drug therapy to all Buckeye members. Buckeye works with providers and pharmacists to ensure that medications used to treat a variety of conditions and diseases are covered. Buckeye covers prescription medications and certain over- the-counter (OTC) medications when ordered by a physician/clinician. The Pharmacy program covers all medically necessary Medicaid covered drugs. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. This section provides an overview of the Buckeye pharmacy program. For more detailed information, please visit our website at www.buckeyehealthplan.com. The following program covers both the Covered Families & Children (CFC) and Aged, Blind or Disabled (ABD) Ohio Medicaid consumers who are enrolled inBuckeye. Plan Preferred Drug List The Buckeye Preferred Drug List (PDL) describes the circumstances under which contracted pharmacy providers will be reimbursed for medications dispensed to members covered under the program. All drugs covered under the Ohio Medicaid program are available for Buckeye members. The PDL includes all drugs available without PA, drugs that require PA, and those agents that have the restrictions of Step Therapy (ST). The PDL applies to drugs you receive at retail pharmacies. The PDL is continually evaluated by the Buckeye Pharmacy and Therapeutics (P&T) Committee to promote the appropriate and cost-effective use of medications. The Committee is composed of the Buckeye Medical Director, Buckeye Pharmacy Director, Buckeye Clinical Pharmacists, and several Ohio primary care physicians, pharmacists, and specialists.
    [Show full text]
  • First-Generation Antihistamines (Medications Commonly Used To
    High­risk medication reference sheet The Pharmacy Quality Alliance has determined the following medications have the highest risk of side effects among those 65 years of age or older. “High­risk” means a medicine can cause serious health problems or accidents. High­risk medications can be: • A medicine that raises your risk of drowsiness, confusion, depression, organ damage, serious harm from a fall, or other dangerous side effects. • A medicine for one health problem that worsens another health problem. • Two or more medications that are dangerous when taken together. The more medicines you take, the greater the risk of negative interactions. Please review the list of high­risk medications below. If you are taking one or more of the medications listed, please speak with your doctor to determine if there are safer choices with fewer possible side effects. First­generation antihistamines (medications commonly used to treat allergies) • Brompheniramine • Cyproheptadine • Hydroxyzine • Carbinoxamine • Dexchlorpheniramine • Promethazine • Chlorpheniramine • Diphenhydramine (oral) • Triprolidine • Clemastine • Doxylamine Anti­Parkinson agents (to treat Parkinson’s disease) • Benztropine (oral) • Trihexyphenidyl Anti­thrombotics (medications used to prevent blood from clotting inappropriately) • Ticlopidine • Dipyridamole Anti­infective (medication used to treat infections) • Nitrofurantoin (only when taken for 90 days or more) Alpha blockers (medications that help blood vessels remain open) • Guanfacine • Reserpine (only if you take more than
    [Show full text]
  • High Risk Medication Alternative Table
    High Risk Medication Alternative Table Description High Risk Medication Rationale for risk* Alternatives Anticholinergics brompheniramine3, Highly anticholinergic, clearance Allergy: levocetirizine, desloratadine, montelukast, carbinoxamine3, reduced with advanced age, and azelastine, intranasal steroid (e.g., fluticasone4), OTCs chlorpheniramine3, tolerance develops when used as such as cetirizine, loratadine, fexofenadine, or clemastine3, cyproheptadine1, hypnotic; greater risk of confusion, dry intranasal normal saline (member to pay out of dexbrompheniramine3, mouth, constipation, and other pocket) dexchlorpheniramine3, anticholinergic effects and toxicity. Cough: OTCs such as guaifenesin, dextromethorphan diphenhydramine (oral)3, (member to pay out of pocket) dimenhydrinate3, Anti-emetic: ondansetron-oral1, granisetron-oral1, doxylamine3, hydroxyzine1, aprepitant-oral1 meclizine, promethazine1, triprolidine3 benztropine (oral)1, Not recommended for prevention of carbidopa & levodopa, carbidopa & levodopa & trihexyphenidyl1 extrapyramidal symptoms with entacapone, ropinirole, pramipexole, amantadine antipsychotics; more-effective agents available for treatment of Parkinson's disease. Antithrombotics dipyridamole - oral short May cause orthostatic hypotension; dipyridamole & aspirin4, clopidogrel acting1 (does not apply to ER more effective alternatives available; combination with aspirin) intravenous form acceptable for use in cardiac stress testing. Anti-infective nitrofurantoin Potential for pulmonary toxicity; safer For UTI Treatment,
    [Show full text]
  • Modified Monoterpene Indole Alkaloid Production in the Yeast Saccharomyces Cerevisiae Copyright © 2017 by Amy M. Ehrenworth
    MODIFIED MONOTERPENE INDOLE ALKALOID PRODUCTION IN THE YEAST SACCHAROMYCES CEREVISIAE A Dissertation Presented to The Academic Faculty by Amy M. Ehrenworth In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the School of Chemistry and Biochemistry Georgia Institute of Technology December, 2017 COPYRIGHT © 2017 BY AMY M. EHRENWORTH MODIFIED MONOTERPENE INDOLE ALKALOID PRODUCTION IN THE YEAST SACCHAROMYCES CEREVISIAE Approved by: Dr. Pamela Peralta-Yahya, Advisor Dr. Francesca Storici School of Chemistry and Biochemistry School of Biological Studies Georgia Institute of Technology Georgia Institute of Technology Dr. M.G. Finn Dr. Loren Williams School of Chemistry and Biochemistry School of Chemistry and Biochemistry Georgia Institute of Technology Georgia Institute of Technology Dr. Wendy L. Kelly School of Chemistry and Biochemistry Georgia Institute of Technology Date Approved: August 14, 2017 ACKNOWLEDGEMENTS I would like to thank all those who’ve guided me on my scientific and personal journey. I was blessed by the circumstances that have led me to this point, and I hope to make those who have influenced and inspired me proud. I want to express gratitude to my advisor Pamela Peralta-Yahya for all she has done for me in my time at Georgia Tech- from introducing me to the incredible field of synthetic biology and sharing her knowledge to helping make me a better scientist. I admire her dedication and ambition, and I am honored to have helped establish the Peralta-Yayha lab. I also appreciate the guidance I’ve received from all of my committee members throughout the years, be it via scientific discussions, mentorship, or personal inspiration.
    [Show full text]